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To the Editor: Persistent iatrogenic atrial septal defect (iASD) after
transseptal puncture for radiofrequency (RF) ablation of atrial
ﬁbrillation (AF) using 8-F sheaths has been reported at rates of
0 to 19% at medium-term follow-up, depending on the transseptal
puncture technique, the follow-up interval, and whether trans-
thoracic echocardiography (TTE) or transesophageal echocardi-
ography was used for assessment (1). Cryoballoon ablation is an
emerging technology for the treatment of patients with AF that
uses a 12-F inner diameter (15-F outer diameter) sheath (FlexCath,
Medtronic, Minneapolis, Minnesota). The effect of this larger
sheath size is poorly described; a single study using transesophageal
follow-up in only 13 patients (without a comparison group) re-
ported residual iASD in 38% at 6 months and 31% at 9 months (2).
We aimed to assess the prevalence of persistent iASD in a larger
group undergoing cryoballoon ablation of AF compared with RF
ablation.
We performed a retrospective analysis of consecutive patients
who underwent ﬁrst-time cryoballoon ablation of AF between
October 2011 and July 2012 and matched them with consecutive
patients who were treated with RF ablation. TTE, including
Doppler interrogation of the interatrial septum, was performed in
all patients before ablation and again at follow-up. Patients with
patent foramen ovale or prior transseptal puncture were excluded,
as were those without a follow-up TTE at least 1 month post-
procedure. TTEs were read and adjudicated for persistence of
iASD by a reviewer blinded to the type of ablation. Continuous
variables are presented as mean  SD. Means were compared with
Student t test and categorical variables with chi-square test or Fisher
exact test as appropriate. All tests were 2-sided, and a p value
of <0.05 was considered signiﬁcant. Analysis was performed using
SPSS (PASW Statistics release 18; IBM, Armonk, New York).
Of 63 consecutive patients undergoing cryoballoon ablation,
10 were excluded due to prior transseptal catheterization and
11 due to lack of post-procedure TTE. The remaining 42 patients
were matched with 42 consecutive patients undergoing RF ablation
after applying the same exclusion criteria. Baseline characteristics
were similar between groups; mean age was 59.9  11.3 versus
60.6  8.9 years, 38.1% versus 33.3% were female, 76.2% versus
69.0% had paroxysmal AF, 35.7% versus 38.1% had structural heart
disease, 9.5% versus 11.9% had left ventricular systolic dysfunction,
and 40.5% versus 42.9% were treated with dabigatran for peri-
procedural anticoagulation, respectively. Double transseptal punc-
ture with two 8-F sheaths was used in all patients undergoing RF
ablation. Twenty of the cryoballoon procedures (47.6%) included
a single transseptal puncture through which the 12-F sheath was
advanced, and 22 (52.4%) included an additional 8-F transseptal
puncture for the circular mapping catheter.
Follow-up TTE was performed 118.2  40.7 days post-
procedure (114.7  27.3 days for the cryoballoon group vs. 121.6
 50.8 days for the RF group; p ¼ 0.44). Seven new iASDs were
detected in the cryoballoon group (16.7%) versus 1 (2.4%) inthe RF group (p ¼ 0.029). In the cryoballoon group, multiple
univariate analyses of age, sex, type of AF, structural heart
disease, double or single transseptal puncture, duration of proce-
dure, and type of anticoagulant did not predict persistent iASD.
AF recurred in 2 (28.6%) and 17 (50%) patients with and
without iASD (p ¼ 0.271), respectively, during a mean follow-up
of 228.0  96.5 days. No new migraine or embolic events
were noted. One patient with a persistent iASD (Fig. 1) reported
reduced exercise capacity post-procedure; magnetic resonance
imaging demonstrated moderate left superior and inferior
pulmonary vein stenosis in addition to iASD, quantitative lung
perfusion scan was normal, and cardiac catheterization demon-
strated no gradient between the left pulmonary veins and the left
atrium. The iASD was therefore believed to be the cause of the
patient’s symptoms. It was measured at 10.4 mm and closed with
a 25-mm Helex device (Gore, Flagstaff, Arizona) 303 days post-
procedure with subsequent resolution of the patient’s symptoms.
Another patient with persistent iASD and heart failure (left
ventricular ejection fraction of 20%) had a signiﬁcant “step up” in
the right ventricle at subsequent right heart catheterization during
an episode of decompensation. A 5  5–mm defect in the
interatrial septum was noted and repaired during implantation of
a ventricular assist device 177 days post-procedure. It was not clear
in either case whether the iASD played a deﬁnitive role in the
symptoms.
Persistent iASD was signiﬁcantly more common after cryo-
balloon ablation than RF ablation and was not predicted by clinical
variables in this patient sample. Although this study was retrospective
and nonrandomized, similar baseline patient variables and the absence
of an effect of procedure duration, number of transseptal punctures,
and type of anticoagulant suggests that this ﬁnding is due to the
larger sheath size of the cryoballoon system. It is possible that
manipulation of the relatively stiff sheath and balloon catheter,
sometimes including so-called advanced maneuvers to satisfactorily
occlude the right inferior pulmonary vein, may stretch the interatrial
septum and have an additive effect on the incidence of iASD beyond
that accounted for by sheath size alone. We did not prospectively
record the use of speciﬁc maneuvers and therefore were unable to
formally analyze for an association with persistent iASD. Although
all transseptal punctures were performed through the fossa ovalis
guided by intracardiac echocardiography, a slightly more anterior
site was often targeted for cryoballoon procedures, and we cannot
exclude the possibility that a systematic difference in puncture site
inﬂuencedour results.Our estimatemay be aminimumvalue given the
suboptimal sensitivity of TTE for detection of small secundum-type
ASDs (3).
There are few data on the long-term effects of such iASDs. A
prospective transesophageal study of patients receiving the
Watchman left atrial appendage occlusion device, delivered
through a slightly smaller sheath with a 14-F outer diameter, found
an incidence of iASD of 34% at 45 days, which decreased to 7% at
Figure 1
Color Doppler Echocardiogram in the Subcostal View
at End Diastole
Echocardiogram in the subcostal view at end diastole showing left-to-right ﬂow at
183 days post-procedure.
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14921 year, and did not report any adverse effects (4). Likewise, adverse
effects attributable to iASD were not reported in the recently
published prospective STOP-AF (Sustained Treatment Of
Paroxysmal Atrial Fibrillation) trial; however, this was not a pre-
deﬁned endpoint and the study did not report post-procedure
echocardiographic imaging (5). In our experience, 2 patients
experienced symptoms or had documented hemodynamic signiﬁ-
cance in the course of follow-up. This suggests that we should be
vigilant with regard to the effect of a larger transseptal sheath size
and that further study is required to determine long-term sequelae
and spontaneous closure rates over time.Edmond M. Cronin, MB BCh BAO
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Invasive Hemodynamic
Assessment of “Paradoxical”
Low-Flow Severe Aortic StenosisWe read with interest the paper by Lauten et al. (1) discussing the
invasive hemodynamic characteristics of low-gradient, severe
aortic stenosis (AS) despite preserved ejection fraction. The
authors’ main ﬁnding was that low-gradient, severe AS despite
preserved ejection fraction was not merely the result of a system-
atic bias in the echocardiographic calculation of the aortic valve
area (AVA) as a result of measurement error and so forth, but was
in fact a real entity as conﬁrmed by invasively derived hemody-
namic data using both the thermodilution and the oxygen
consumption methods for stroke volume, cardiac output, and
AVA calculation. This is an important study, but we would like to
draw attention to the following limitations. First, criteria for
inclusion in the study required an AVA <1 cm2, a mean
gradient 40 mm Hg, and an ejection fraction 50%. However,
by not using the indexed AVA as an inclusion criterion, there
remains the possibility that small body size could explain why at
least some patients presented with guideline-discordant AVA and
gradient patterns in both the echocardiography and invasive
catheterization groups (2). Second, not all patients in the low-
gradient group had a low stroke volume index (Table 3 in the
article); therefore, these patients may have had a low gradient
secondary to the inherent inconsistent grading related to
discrepancy in guidelines criteria and not due to paradoxical low-
ﬂow, low-gradient, severe AS per se (2). Third, the calculated
valvulo-arterial impedance (Zva) cannot be considered accurate
given the fact that the systolic arterial pressure was not measured
at the time of stroke volume calculation during echocardiography
but instead “was taken from the closest recorded non-invasive
measurement in the patient charts.” In fact, a more accurate
assessment of the Zva could have been derived invasively by
dividing the left ventricular systolic pressure by the stroke volume
index (3). Finally, the authors found that compared with patients
with high-gradient severe AS, patients with “paradoxical” low-
gradient, severe AS had higher energy loss index values, larger
AVA values, similar Zva values, lower left ventricular mass index
values, and lower mean gradient values. Taken together, these
ﬁndings imply that patients with “paradoxical” low-gradient AS have
a less severe form of AS compared with patients with high-gradient,
severe AS. These ﬁndings therefore contradict two recent studies
(4,5) that found that patients with “paradoxical” severe AS had
